Gururangan, S., Vredenburgh, J. J., Desjardins, A., Peters, K., Herndon, J. E., McLendon, R. E., … Reardon, D. A. (2010). CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma. Journal of Clinical Oncology, 28(15_suppl), 2089–2089. https://doi.org/10.1200/jco.2010.28.15_suppl.2089

Gururangan, S., J. J. Vredenburgh, A. Desjardins, K. Peters, J. E. Herndon, R. E. McLendon, D. Janney, H. S. Friedman, and D. A. Reardon. “CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2089–2089. https://doi.org/10.1200/jco.2010.28.15_suppl.2089.

Gururangan S, Vredenburgh JJ, Desjardins A, Peters K, Herndon JE, McLendon RE, et al. CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma. Journal of Clinical Oncology. 2010 May 20;28(15_suppl):2089–2089.

Gururangan, S., et al. “CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma.” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 2089–2089. Crossref, doi:10.1200/jco.2010.28.15_suppl.2089.

Gururangan S, Vredenburgh JJ, Desjardins A, Peters K, Herndon JE, McLendon RE, Janney D, Friedman HS, Reardon DA. CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):2089–2089.